BDA-366, a Bcl-2-BH4 domain antagonist, can induce conformations to change in the exposure of the BH3 domain and abrogate the anti-apoptotic function of Bcl-2, and further inhibit tumor growth of lung cancer and multiple myeloma [35, 36]. This evidence concerns the gene BCL2 and lung carcinoma.